Aerie Pharmaceuticals, the biotech firm backed by TPG Biotech, the life science venture unit of private equity firm TPG, has raised $3m towards a $15m round of debt, rights and securities. Aerie develops treatments for glaucoma.
Aerie has raised a total of $61m. Early last year the company raised $30m in series B funding from Alta Partners, Clarus Ventures, Osage Ventures, Sofinnova Ventures and TPG Biotech.
TPG recently recently returned to participate in a $10m round of funding for drug company Trevi Therapeutics.